<DOC>
	<DOCNO>NCT01889199</DOCNO>
	<brief_summary>The purpose research study collect specimen sample study medical information woman Polycystic Ovary Syndrome ( PCOS ) woman without PCOS . The goal learn change take place body result PCOS . We anticipate 59 woman take part study ( 15 without PCOS 44 PCOS ) . All patient undergo physical exam , blood test , ultrasound ovary . If meet criterion study , undergo additional blood test , removal small amount subcutaneous abdominal fat , measurement regional body fat ( i.e. , MRI , DXA scan ) , modify frequently-sampled intravenous glucose tolerance test ( FSIGTT ) , determination ovarian function ( via follicle stimulate hormone [ FSH ] test ) . The woman without PCOS complete study point . The woman PCOS randomize receive drug flutamide 125 mg/day placebo . They take drug every day six 28-day cycle . They ask collect store urine sample week . They also ask complete pill diary menstrual diary . Once month take flutamide/placebo , return clinic bring frozen urine sample . At time undergo physical exam , toxicity assessment , blood draw . Quality Life assessment do begin study participant . Women PCOS take flutamide placebo ask repeat Quality Life assessment study end study . Six month follow completion protocol procedure , participant receive flutamide/placebo contact phone check status health . They ask experienced health problem become pregnant since complete study procedure . After six 28-day cycle complete undergo additional blood test , removal small amount subcutaneous abdominal fat , measurement regional body fat ( i.e. , MRI , DXA scan ) , modify frequently-sampled intravenous glucose tolerance test ( FSIGTT ) , determination ovarian function ( via FSH test ) .</brief_summary>
	<brief_title>Androgen Excess Mechanism Adipogenic Dysfunction PCOS Women</brief_title>
	<detailed_description>Aim 1 . Compare differences SC abdominal adipogenesis lean PCOS woman vs. age- BMI-matched control Subjects clinical assessment : We recruit 36 lean ( 18.5-25 kg/M2 ) PCOS subject 12 age- BMI-matched control . Subjects complete standardize questionnaire emphasize menstrual dating , abnormal hair growth acne . The questionnaire also annotate age , smoke status , medication , surgical history family histories excess hair growth female relatives diabetes parent sibling exclusion criterion inclusion basic trait covariates . Subjects also undergo physical examination ; hirsutism score modify Ferriman-Gallwey ( mFG ) method . Transvaginal sonography ( TVUS ) perform determine presence absence polycystic ovary . A screening blood sample obtain determination steroid hormone , SHBG , TSH , prolactin . Non-Hispanic Caucasian woman age 18 35 year recruit avoid confound difference function race . PCOS patient diagnose 1990 NIH criterion . Controls regular menstrual cycle 21 35 day interval , luteal phase progesterone ( P4 ) level &gt; 3 ng/mL , evidence hirsutism , acne , alopecia , polycystic ovary endocrine dysfunction . Exclusion criterion : present/past history ( &lt; 5 year ) smoking , cancer , alcohol abuse , drug addiction , severe depression , post traumatic stress ; diabetes ; uncontrolled hypertension ( ≥ 165/100 ) ; clinically significant hepatic renal disease , major medical illness ; sign symptom infection ; recent ( within 30 day ) use experimental device ; recent ( within 6 month ) use androgen , anabolic steroid non-steroidal anti-inflammatory drug ; recent ( within 3 month ) use hormonal agent ( include birth control pills insulin sensitizer ) ; use drug warfarin . Studies conduct follicular phase control amenorrhea PCOS woman . All subject undergo modify frequently-sampled intravenous glucose tolerance test ( FSIGTT ) . Glucose form 50 % solution ( 0.3 g/kg ) regular human insulin ( 0.03 units/kg ) inject intravenous line 0 20 min , respectively . Blood collect -20 , -15 , −5 , 0 , 2 , 4 , 8 , 19 , 22 , 30 , 40 , 50 , 70 , 90 , 180 min glucose insulin determination . Mathematical model serial glucose insulin determination calculate : insulin sensitivity index ( SI , i.e . action insulin accelerate glucose uptake suppress glucose production ) , glucose effectiveness index ( SG , i.e . combine effect glucose enhance glucose uptake suppress endogenous glucose production basal insulin level ) acute response glucose ( AIRG ) . Adipocytes isolation culture : Approximately 1-3 gm fat obtain low SC abdomen use standard procedure local anesthesia . Adipocytes ( fat cell ) surround fat tissue isolate measure adipocyte cell number diameter , lipid accumulation function , adiponectin , stem cell development . Procedures : All procedure perform normal PCOS woman start study . ) . Venipuncture : Fasting blood collect blood count , chemistry panel , LH , FSH , total/free T , DHT , A4 , DHEAS , E1 , E2 , anti-mullerian hormone ( AMH ) , SHBG , adiponectin , IL-6 , lipid profile free fatty acid ( FFAs ) . ii ) . Body composition : Body composition assess BMI , waist-to-hip circumference DEXA scanning . Girths measure waist ( narrow section torso rib umbilicus ) hip ( large protrusion hip region , gluteal fold ) . For total body fat regional fat distribution , whole body scan perform , utilize DEXA imaging . iii ) . Body fat distribution : Total body DEXA measure abdominal fat ( i.e. , area dome diaphragm top hip . Total body DEXA image also determine % body fat ; fat-free body mass ; total body , abdominal , leg fat ; abdomen/leg fat mass ratio . The leg region area top hip bone ( great trochanter ) . Multiple axial abdominal MRI slice diaphragm pelvis assess cross-sectional area SC abdominal visceral fat . iv ) . Ovarian testing : 1 . Ovarian morphology : Transvaginal ultrasound perform follicular phase control amenorrhea PCOS woman . Ovarian volume calculate . Antral follicle number , define total follicle number ( 2-9 mm diameter ) ovary , determine 1 investigator ( D.A.D. ) . Polycystic ovary define 12 follicle ovary measure 2-9 mm diameter , and/or increase ovarian volume ( &gt; 10 ml ) , one ovary sufficient define PCO . 2 . Estradiol ( E2 ) response recombinant human ( rh ) FSH . Blood sample draw indwell iv catheter 0.5-h interval 2 h 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 h 150 U rhFSH injection . The E2 response rhFSH assess adjust number TVUS-detected ovarian antral follicle . Aim 2 . Examine effect flutamide lean PCOS woman SC abdominal adipogenesis , visceral adipose content ovarian folliculogenesis . Modified FSIGTT Adipogenic study : The modified FSIGTT adipogenic study perform study initiation repeat end 6-month flutamide vs. placebo intervention PCOS woman . Procedures : All procedure perform study initiation also repeat end six 28-day cycle flutamide vs. placebo intervention PCOS woman . In addition , monthly liver function study perform detect possible elevation serum transaminase level normal range flutamide vs. placebo therapy . Menstrual record urinary pregnanediol glucuronide ( UPDG ) : Ovulatory frequency determine subject keep daily menstrual record collect weekly first morning urine sample UPDG creatinine assay . Urine sample frozen late analysis determine evidence ovulation .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>NonHispanic Caucasian woman age 18 35 year . Groups : 12 lean control ( Aim 1 ) ; 36 age BMImatched PCOS woman randomize flutamide vs. placebo 6 month ( Aims 1 2 ) . ) Lean patient PCOS : 36 subject PCOS ( defined 1990 NIH criterion [ Aims ] ) , BMI 18.525 kg/m2 . This BMI range define normal chosen examine underlie mechanism PCOSrelated androgen excess genesis adipogenic ovarian dysfunction , independent obesity . ii ) Lean control woman : 12 healthy subject , BMI 18.525 kg/m2 . Controls regular menstrual cycle , evidence hirsutism , acne , alopecia , polycystic ovary , and/or endocrine dysfunction . This BMI range chosen match PCOS group . Up 44 lean PCOS patient 15 lean control recruit , total 59 study participant 5year interval , account 20 % rate patient dropout insufficient adipose procurement . Exclusion criterion study participation : present past history ( &lt; 5 year ) smoking , cancer , alcohol abuse , drug addiction , severe depression , post traumatic stress ; diabetes ; uncontrolled hypertension ( ≥ 165/100 ) ; clinically significant hepatic renal disease , major medical illness ; recent ( within 3 month ) use androgen , anabolic steroid hormonal agent ( include birth control pills insulin sensitizer ) . These exclusion criterion choose avoid effect medical condition , environmental factor exogenous agent . Women take drug warfarin , CYP active medication , herb exclude . Since study involve MRI testing , woman pacemaker , metal implant , claustrophobia exclude . The screener assess participant response establish depression drug use exclude participation study . Women take beta blocker exclude . Women take birth control pills Mirena IUD use Plan B contraception previous 3 month exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>polycystic ovary syndrome</keyword>
	<keyword>hirsutism</keyword>
	<keyword>anovulation</keyword>
	<keyword>oligomenorrhea</keyword>
	<keyword>amenorrhea</keyword>
	<keyword>hyperandrogenism</keyword>
	<keyword>antiandrogen effect</keyword>
</DOC>